6 (tied). Gossamer Bio
Venture capital raised: $100 million
The company is developing therapeutic products that specialize in oncology, inflammation, immunology and fibrosis. Gossamer Bio currently has a number of therapies in its pipeline for a variety of conditions, including inflammatory bowel disease, chronic spontaneous urticaria and pulmonary arterial hypertension.
You may also like: